Daily Anesthesiology Research Analysis
Analyzed 128 papers and selected 3 impactful papers.
Summary
Three anesthesia-focused studies stand out today: a randomized trial shows sugammadex reduces postoperative urinary retention versus neostigmine after laparoscopic cholecystectomy; a four-arm randomized trial demonstrates that Oxygen Reserve Index-guided management reduces desaturation during deep sedation hysteroscopy; and a meta-analysis of pediatric RCTs finds remimazolam lowers emergence delirium without prolonging recovery.
Research Themes
- Neuromuscular block reversal and postoperative outcomes
- Physiologic monitoring (ORI) to prevent hypoxemia during deep sedation
- Pediatric emergence delirium mitigation with remimazolam
Selected Articles
1. Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine versus Sugammadex in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Controlled Trial.
In 235 randomized patients undergoing laparoscopic cholecystectomy with rocuronium-based anesthesia, reversal with sugammadex (2 mg/kg TBW) significantly reduced postoperative urinary retention compared with neostigmine plus glycopyrrolate. No major adverse events occurred.
Impact: This is the first prospective RCT directly comparing reversal agents on POUR in a common ambulatory procedure, providing actionable evidence for drug selection to facilitate same-day discharge.
Clinical Implications: Prefer sugammadex over neostigmine for reversal after laparoscopic cholecystectomy to reduce POUR and potentially shorten PACU time and unplanned admissions. Incorporate bladder ultrasound-based definitions in ERAS pathways.
Key Findings
- Sugammadex reduced the incidence of POUR by an absolute 12.8% versus neostigmine (P < .001).
- Objective POUR criteria included inability to void with bladder volume ≥300 mL or post-void residual ≥200 mL, or the need for catheterization.
- No major adverse events were reported in either group.
Methodological Strengths
- Prospective randomized controlled design with clear, objective primary endpoint.
- Standardized anesthetic protocol with ultrasound-based bladder assessments.
Limitations
- Single procedure context (laparoscopic cholecystectomy) may limit generalizability to other surgeries.
- Blinding and allocation concealment details are not specified in the abstract.
Future Directions: Evaluate POUR and discharge readiness across diverse surgical populations and explore cost-effectiveness and patient-centered outcomes with sugammadex-based pathways.
BACKGROUND: In an era of fast-track surgery and enhanced recovery protocols, postoperative urinary retention (POUR) remains a common barrier to same-day discharge, contributing to prolonged PACU stays, patient discomfort, and unplanned admissions. Although sugammadex has been associated with a reduced incidence of POUR, no prospective, randomized studies have compared neostigmine and sugammadex for neuromuscular blockade reversal in laparoscopic cholecystectomy. The objective of this study was to determine the incidence of postoperative urinary retentio
2. Oxygen reserve index monitoring reduced the incidence of low pulse oxygen saturation during deep sedation for hysteroscopy: a prospective randomized controlled trial.
In a 4-arm randomized trial of 400 patients undergoing deep sedation hysteroscopy, ORI-guided management triggered earlier assisted ventilation and reduced the incidence of low SpO2 compared with standard pulse oximetry-triggered responses. Use of a nasopharyngeal airway further mitigated desaturation versus face mask.
Impact: Demonstrates that a physiologic, noninvasive monitoring metric (ORI) can anticipate desaturation and change clinician behavior to prevent hypoxemia during deep sedation.
Clinical Implications: Incorporate ORI monitoring with predefined intervention thresholds during deep sedation cases at risk of rapid desaturation, and consider routine use of nasopharyngeal airways to minimize hypoxemia.
Key Findings
- Randomization of 400 hysteroscopy cases into ORI+FM, ORI+NPA, non-ORI+FM, and non-ORI+NPA showed lower low-SpO2 incidence in ORI arms.
- Predefined trigger (ORI reaching zero) allowed earlier assisted ventilation than relying on SpO2 decline.
- Nasopharyngeal airway use further reduced desaturation compared with face mask oxygen delivery.
Methodological Strengths
- Prospective randomized four-arm design with 1:1:1:1 allocation.
- Protocolized intervention thresholds tied to physiologic monitoring versus standard care.
Limitations
- Outcomes and exact effect sizes are not fully detailed in the abstract excerpt.
- Generalizability beyond deep sedation hysteroscopy and to non-ORI devices is uncertain.
Future Directions: Quantify effect sizes across procedures and sedation depths; evaluate cost-effectiveness and integration with capnography and high-flow oxygen strategies.
OBJECTIVE: Low pulse oxygen saturation (SpO METHODS: Based on whether ORI monitoring was adopted or not, and the oxygen supply methods during procedure [through face mask (FM) or nasopharyngeal airway (NPA)], four hundred participants underwent hysteroscopy under deep sedation were randomly divided into ORI+FM group, ORI+NPA group, non-ORI+FM group, and non-ORI+NPA group in a 1:1:1:1 ratio. Assist ventilation was performed when ORI dropped to zero in ORI monitoring groups, it was performed when SpO RESULTS: Compared to non-ORI monitoring groups, the incidence of low SpO CONCLUSION: During deep sedation for hysteroscopy, ORI monitoring and the altered clinician behavior from it may related to the reducing of the incidence of low SpO CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/search?term=NCT05701839, identifier NCT05701839.
3. The Effect of Remimazolam Administration on Emergence Delirium in Children After General Anesthesia: A Systematic Review With Meta-Analysis of Randomized Controlled Trials.
This meta-analysis of 10 pediatric RCTs (n=1231) found that remimazolam reduces emergence delirium incidence (RR 0.38) and PAED scores, with fewer bradycardia events. Compared with propofol, remimazolam was associated with less hypotension and shorter extubation time; PACU stay and PONV were similar.
Impact: Aggregates randomized evidence supporting a practical pharmacologic strategy to prevent pediatric emergence delirium without compromising hemodynamics or recovery.
Clinical Implications: Consider remimazolam as part of pediatric anesthetic plans where emergence delirium risk is high, especially when minimizing hypotension and expediting extubation are priorities.
Key Findings
- Remimazolam reduced emergence delirium incidence (RR 0.38, 95% CI 0.23–0.63).
- PAED scores decreased (MD −1.70), and bradycardia was less frequent (RR 0.39).
- Versus propofol, remimazolam had less hypotension (RR 0.14 in subgroup) and shorter extubation time (MD −3.36 s).
Methodological Strengths
- Systematic review and meta-analysis limited to randomized controlled trials.
- Predefined outcomes with random-effects modeling and subgroup analyses.
Limitations
- Heterogeneity in comparators, dosing regimens, and anesthesia contexts across included trials.
- Long-term neurobehavioral outcomes were not addressed.
Future Directions: Head-to-head pediatric trials versus common regimens with standardized dosing and core outcome sets; evaluate long-term behavioral and cognitive outcomes.
BACKGROUND: Emergence delirium commonly occurs in pediatric patients after general anesthesia, causing distress and potential harm. Remimazolam, an ultra-short-acting benzodiazepine, has recently been introduced in pediatric anesthesia, but its preventive role against emergence delirium remains unclear. AIMS: This systematic review with meta-analysis evaluated the effect of remimazolam on the incidence and severity of emergence delirium in children undergoing general anesthesia. METHODS: PubMed, EMBASE, CENTRAL, Scopus, Web of Science, and Google Scholar were searched for relevant studies. The primary outcome was the incidence of emergence delirium. Secondary outcomes included Pediatric Anesthesia Emergence Delirium score, incidence of hypotension and bradycardia, extubation time, postanesthesia care unit stay, and postoperative nausea and vomiting incidence. Relative risks (RR) or mean difference (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. RESULTS: Ten randomized controlled trials involving 1231 children were included. Remimazolam significantly reduced the incidence of emergence delirium (RR 0.38, 95% CI 0.23-0.63; p = 0.0002) and Pediatric Anesthesia Emergence Delirium score (MD -1.70, 95% CI -2.77 to -0.63; p = 0.0019). It also decreased bradycardia (RR 0.39, 95% CI 0.21-0.70; p = 0.0018). Although the overall incidence of hypotension did not differ significantly (RR 0.35, p = 0.0991), subgroup analysis showed a lower incidence with remimazolam than with propofol (RR 0.14, p = 0.0376). Overall extubation time was comparable (MD -0.75, p = 0.5088), but shorter with remimazolam than propofol (MD -3.36, p < 0.0001). No significant differences were found in postanesthesia care unit stay or postoperative nausea and vomiting. CONCLUSIONS: Remimazolam may reduce the incidence and severity of emergence delirium in children after general anesthesia, without affecting hemodynamic stability or recovery time. TRIAL REGISTRATION: PROSPERO: CRD420251236789.